diabetestalk.net

Medtronic Trauma Products

Medtronic Entry Level Jobs And Internships

Medtronic Entry Level Jobs And Internships

Medtronic, Inc. (Medtronic) is a global player in medical technology. The Company operates in seven segments that manufacture and sell device-based medical therapies: Cardiac Rhythm Disease Management, Spinal, CardioVascular, Neuromodulation, Diabetes, Surgical Technologies and Physio-Control. Through these seven segments, the Company develops, manufactures and markets its medical devices in more than 120 countries. Its primary products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, diabetes, and ear, nose and throat conditions. The primary markets for products are the United States, Western Europe and Japan. In July 2008, it acquired Restore Medical, Inc. In November 2008, Medtronic acquired CryoCath Technologies Inc. In February 2009, it acquired Ablation Frontiers, Inc. and Ventor Technologies Ltd. In April 2009, Medtronic acquired CoreValve, Inc.(Source: 10-K) Medtronic, Inc. (Medtronic) is a global player in medical technology. The Company operates in seven segments that manufacture and sell device-based medical therapies: Cardiac Rhythm Disease Management, Spinal, CardioVascular, Neuromodulation, Diabetes, Surgical Technologies and Physio-Control. Through these seven segments, the Company develops, manufactures and markets its medical devices in more than 120 countries. Its primary products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive ... Continue reading >>

Medtronic Plc (mdt) Company Profile | Reuters.com

Medtronic Plc (mdt) Company Profile | Reuters.com

Medtronic Public Limited Company (Medtronic), incorporated on June 12, 2014, is a medical technology, services and solutions company. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes cardiac rhythm and heart failure, coronary and structural heart, and aortic and peripheral vascular. Its Minimally Invasive Therapies Group segment includes surgical solutions, and patient monitoring and recovery. Its Restorative Therapies Group segment includes spine, neuromodulation, surgical technologies and neurovascular. Its Diabetes Group segment includes intensive insulin management, non-intensive diabetes therapies, and diabetes services and solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc. The Company's Cardiac Rhythm & Heart Failure Disease Management (CRHF) division develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failure. Its products include implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), products designed to reduce surgical site infections, information systems for the management of patients with CRHF devices and an integrated health solutions business. The Company's Implantable Cardiac Pacemakers (Pacemakers) include Advisa MRI SureScan models, the Micra Transcatheter Pacing System and the Ensura MRI SureScan model. Its Implantable Cardioverter Defibrillators (ICDs) include Evera MRI SureScan. The Company's Implantable Cardiac Resynchronization Therapy Devices (CRT-Ds and CRT-Ps) consist of CRT-Ds, which include Amplia/Compia/Claria family of MRI Quad CR Continue reading >>

Medtronic Says Device For Spine Faces Probe

Medtronic Says Device For Spine Faces Probe

Medtronic Says Device for Spine Faces Probe The Department of Justice is investigating the off-label use of a Medtronic Inc. implant for promoting bone growth, bringing government scrutiny of such unapproved uses to the heart of the $189 billion medical-device industry. The probe -- in combination with a government safety warning and whistleblowers' lawsuits -- has created what Medtronic Chief Executive William A. Hawkins termed Tuesday a "perfect storm" that suppressed sales of Infuse Bone Graft. The biologically engineered protein is widely used in surgeries... Copyright 2018 Dow Jones & Company , Inc. All Rights Reserved.

  • Save Article
    Sign In to Save Subscribe to WSJ
  • Continue reading >>

  • 25 Things To Know About Medtronic

    25 Things To Know About Medtronic

    Written by Mary Rechtoris| June 25, 2015| Print | Email Medtronic is the world's third largest medical device company specializing in technology, services and solutions. Here are 25 things to know about Medtronic: 1. The company has more than 85,000 employees and 53,000 patents in more than 160 countries. 2. Medtronic has its principal executive offices located in Ireland with its operational headquarters based in Minneapolis. 3. Medtronic is presently the world leader in spinal and musculoskeletal therapies. The company's second largest business is spinal and biologics. 4. Medtronic was ranked 14th among large companies on Computerworld's "Best Places to Work in IT" in 2015. 5. Medtronic had a total revenue of $20.2 billion in the 2015 fiscal year, up 19 percent. 6. GAAP earnings were $1.7 billion, an increase of 16 percent in 2015. 7. In the fiscal year 2015, diluted earnings per share were up 6 percent to $4.28. Net earnings were $2.6 billion, down 13 percent from 2014. 8. In the last quarter, Medtronic had earnings of $2.3 billion in cardiac and vascular products; $1.7 billion in restorative therapy products; $449 million in diabetes products; and $2.4 billion in Covidien products. 9. In the United States, Medtronic had a quarterly revenue total of $3.8 billion in the current 2015 fiscal year. In the 2014 fiscal year, Medtronic reported total revenue of $14.4 billion in the United States. 10. In 2015, Medtronic's market cap was approximately $100 billion after its acquisition of Covidien. Medtronic purchased Covidien for $49.9 billion as one of the largest transactions among device companies last year. 11. The company's quarterly dividend presently is 38 cents per share, totaling to $1.52 per share. Medtronic's dividend yield is 1.98 percent. 12. Medtronic's curren Continue reading >>

    Aortic Therapies | Medtronic Academy

    Aortic Therapies | Medtronic Academy

    BRIEFSTATEMENT: ENDURANT II/ENDURANTIIs BIFURCATEDSTENTGRAFTSYSTEM The Endurant II/Endurant IIs bifurcated stent graft is indicated for the endovascular treatment of infrarenal abdominal aortic or aorto-iliac aneurysms.The Endurant II aorto-uni-iliac (AUI) stent graft is indicated for the endovascular treatment of infrarenal abdominal aortic or aortoiliac aneurysms in patients whose anatomy does not allow the use of a bifurcated stent graft. The Endurant II/Endurant IIs stent graft system is indicated for use in patients with the following characteristics: Adequate iliac/femoral access that is compatible with vascular access techniques, devices and/or accessories Aortic neck diameters with a range of 19 to 32 mm Iliac diameters with a range of 8 to 25 mm The Endurant II/Endurant IIs Stent Graft System is contraindicated in: Patients who have a condition that threatens to infect the graft. Patients with known sensitivities or allergies to the device materials. The long-term safety and effectiveness of the Endurant II/Endurant IIs Stent Graft System has not been established. All patients should be advised that endovascular treatment requires lifelong, regular follow-up to assess the health and the performance of the implanted endovascular stent graft. Patients with specific clinical findings (e.g., endoleaks, enlarging aneurysms or changes in the structure or position of the endovascular graft) should receive enhanced follow-up. Specific follow-up guidelines are described in the Instructions for Use. Patients experiencing reduced blood flow through the graft limb, aneurysm expansion, and persistent endoleaks may be required to undergo secondary interventions or surgical procedures. The Endurant II/Endurant IIs Stent Graft System is not recommended in patients unable to u Continue reading >>

    Medtronics $816 Million Bet On China Kanghui

    Medtronics $816 Million Bet On China Kanghui

    Medtronics $816 Million Bet on China Kanghui Medtronic, Inc. is placing an $816 million bet on the Chinese orthopedic market by acquiring Chinese orthopedics company, China Kanghui Holdings, for cash. Omar Ishrak, Medtronic's CEO, announced that he pulled the trigger on Medtronic's biggest acquisition since he took charge at the company last year after the markets closed on September 27. He had been less than complimentary of previous acquisition choices by his predecessor, particularly in the spine business. But Omar promised to go global and not give up on spine just yet. He not only stayed committed to spine, but is adding trauma products made for markets outside the U.S. Ishrak said the deal represents a "significant" investment in China. Chris O'Connell, Medtronic's executive vice president and president of the company's Restorative Therapies Group (which includes spine), said Medtronic will now establish a "bigger and more direct local presence" in the country Kanghui brings Medtronic a broad product portfolio, a strong local R&D and manufacturing operation, a vast China distribution network and an exceptional management team. This move will provide Medtronic sustainable advantages in the fast-growing Chinese orthopedic segment, as well as a foothold in the emerging global value segment in orthopedics, said O'Connell. It is unclear what the impact of the acquisition will be on the joint venture that Medtronic has in China with the Weigao Group. Back in 2007, Medtronic entered into a joint venture with Weigao with Medtronic taking a 51% majority stake. Medtronic also took a 15% equity stake in Weigao. "It appears there is significant overlap between Kanghui and Weigao product offerings; therefore we believe Medtronics acquisition of Kanghui will essentially replac Continue reading >>

    Bone Grafting - Spine And Trauma Surgery - Bone Graft Categorization | Medtronic

    Bone Grafting - Spine And Trauma Surgery - Bone Graft Categorization | Medtronic

    BONE GRAFT CATEGORIZATION Bone Grafting (Spine and Orthopaedic) Bone graft selection is critical to the outcome of any bone healing procedure. There are currently over 200 different bone grafts available to surgeons today, each with substantial differences in technology, materials, mechanisms of action, indications, and clinical evidence. Recombinant proteins are naturally occurring proteins that play an active role in bone formation and maintenance. The human sequence of these proteins can be synthetically manufactured in a consistent, controlled process commonly referred to as "human recombinant"technology, or recombinant human bone morphogenetic protein (rhBMP). Composition: (recombinant human proteins) MOA: Highly osteoinductive and provides a strong signal for bone formation Approval: Premarket approval (PMA) Humanitarian device exemption (HDE) Data Required: PMAs require a pivotal human clinical trial to show safety and efficacy. There are many different allograft products or forms available for use. Some allograft tissue functions through osteoconduction and mild osteoinduction when demineralized, and include mineralized tissue, demineralized tissue, and allograft tissue plus cells. These products are also regulated differently based on how they are processed. For example, tissue based products that have a 351 HCT/Ps designation are regulated like a medical device and require a submission to the FDA for clearance. Tissue based products that fall into the minimally manipulated category are regulated as a 361 HCT/P and do not require a submission to the FDA. Demineralized MOA: osteoconductive and osteoinductive. 351 Approval: Formulated allograft products such as DBMs have 510(k) clearance as a bone void filler for applications not intrinsic to the stability of th Continue reading >>

    Bone Grafting - Spine And Trauma Surgery | Medtronic

    Bone Grafting - Spine And Trauma Surgery | Medtronic

    BRIEF SUMMARY OF INDICATIONS, CONTRAINDICATIONS, AND WARNINGS FOR: Infuse Bone Graft/LT-Cage Lumbar Tapered Fusion Device Infuse Bone Graft/Inter Fix Threaded Fusion Device Infuse Bone Graft/Inter Fix RP Threaded Fusion Device Infuse Bone Graft/Perimeter Interbody Fusion Device Infuse Bone Graft/Clydesdale Spinal System Infuse Bone Graft/Divergence-L Anterior/Oblique Lumbar Fusion System Infuse Bone Graft/Pivox Oblique Lateral Spinal System The Infuse Bone Graft/Medtronic Interbody Fusion Device is indicated for spinal fusion procedures in skeletally mature patients with degenerative disc disease (DDD) at one level from L2-S1, who may also have up to Grade I spondylolisthesis or Grade 1 retrolisthesis at the involved level. The following interbody devices and surgical approaches may be used with Infuse Bone Graft: The LT-Cage Lumbar Tapered Fusion Device, implanted via an anterior open or an anterior laparoscopic approach at a single level. The Inter Fix or Inter Fix RP Threaded Fusion Device, implanted via an anterior open approach at a single level. The Perimeter Interbody Fusion Device implanted via a retroperitoneal anterior lumbar interbody fusion (ALIF) at a single level from L2-S1 or an oblique lateral interbody fusion (OLIF) approach at a single level from L5-S1. The Clydesdale Spinal System, implanted via an OLIF approach at a single level from L2-L5. The Divergence-L Anterior/Oblique Lumbar Fusion System interbody device implanted via an ALIF approach at a single level from L2-S1 or an OLIF approach at a single level from L5-S1. The Pivox Oblique Lateral Spinal System implanted via an OLIF approach at a single-level from L2-L5. The Infuse Bone Graft/Medtronic Interbody Fusion Device consists of two components containing three parts a spinal fusion cage, a rec Continue reading >>

    5. Medtronic Spine - Covering The Specialized Field Of Orthopedic Product Development And Manufacturing

    5. Medtronic Spine - Covering The Specialized Field Of Orthopedic Product Development And Manufacturing

    Karen L. Parkhill, Exec. VP and Chief Financial Officer Gary L. Ellis, Exec. VP of Global Operations and Information Technology Bradley E. Lerman, Sr. VP, General Counsel and Corporate Secretary Geoffrey S. Martha, Exec. VP and President, Restorative Therapies Group Robert ten Hoedt, Exec. VP and President, EMEA One of the most beloved movie endings ever filmed almost never made it onscreen. The script for the 1971 musical fantasy Willy Wonka and the Chocolate Factory originally ended with Grandpa Joe shouting, Yippie! and then fading to black. But Emmy award-winning director Mel Stuart wanted a better closing line, and reportedly phoned writer David Seltzer from the set to request a more memorable finale. Seltzer could only come up with one idea, though it was a bit clich. In the films final scenecherished by millions of fans worldwidethe eccentric title character announces he is giving his entire factory to Charlie Bucket, a kind-hearted, honest, but poor boy who lives with his widowed mother and four bedridden grandparents in the slums of an unnamed European city. As Charlies disbelief turns to gratitude, Wonka hugs the boy, then tells him, But Charlie, dont forget what happened to the man who suddenly got everything he always wanted. He lived happily ever after, Wonka replies, smiling. Of course he did. It is a movie, after all. Hollywood is notorious for its happy endings, but such closure is not as readily found off-screen. Fairy tales and their all-is-well finales are pure fiction; the real world doesnt work that wayits cold, inconsistent, and oftentimes unfair. It offers no guarantees on contentment. Joy can be particularly elusive in business, even for companies that follow Wonkas guide to eternal euphoria. Apple Inc.s Cinderella-like evolution, for example, s Continue reading >>

    News Detail

    News Detail

    Medtronic and Weigao Announce Joint Venture in China Medtronic, Inc. and Shandong Weigao Group Medical Polymer Company Limited have announced that they will form a joint venture to market therapies in the spine and orthopedics sector. Medtronic will acquire a 15% equity interest in Weigao. Medtronic, Inc. and Shandong Weigao Group Medical Polymer Company Limited have announced that they will form a joint venture to market therapies in the spine and orthopedics sector. Medtronic will acquire a 15% equity interest in Weigao. The joint venture will market in China Medtronics spinal products and Weigaos orthopedic products which include therapies for the hip, shoulder, spine and trauma. Under the joint venture agreement Medtronic will have a 51% interest in the joint venture and Weigao will have a 49% interest. Medtronic will purchase a 15% equity interest in Weigao for approximately HK$1,726 million (US$221 million) through the purchase of 80,721,081 newly issued H Shares of Weigao that are listed on the Hong Kong Stock Exchange at a purchase price of HK$11.138 per share and an equal number of Weigaos unlisted ordinary shares from Weigaos existing shareholders at a purchase price of HK$10.247 per share. In connection with the purchase of the shares, Medtronic will have the right to nominate two non-executive directors to Weigaos board of directors as long as Medtronic owns 3.75% of the H Shares. Closing of the transaction is subject to various conditions, including approval of the Chinese regulators and Weigaos shareholders. China is key to our global strategy as we continue to expand our geographic footprint, said Bill Hawkins, Medtronic president and CEO. Weigao has a broad orthopedic and trauma product line that compliments Medtronics offerings, but even more important Continue reading >>

    5. Medtronic Spine - Covering The Specialized Field Of Orthopedic Product Development And Manufacturing

    5. Medtronic Spine - Covering The Specialized Field Of Orthopedic Product Development And Manufacturing

    Karen L. Parkhill, Exec. VP and Chief Financial Officer Gary L. Ellis, Exec. VP of Global Operations and Information Technology Bradley E. Lerman, Sr. VP, General Counsel and Corporate Secretary Geoffrey S. Martha, Exec. VP and President, Restorative Therapies Group Robert ten Hoedt, Exec. VP and President, EMEA One of the most beloved movie endings ever filmed almost never made it onscreen. The script for the 1971 musical fantasy Willy Wonka and the Chocolate Factory originally ended with Grandpa Joe shouting, Yippie! and then fading to black. But Emmy award-winning director Mel Stuart wanted a better closing line, and reportedly phoned writer David Seltzer from the set to request a more memorable finale. Seltzer could only come up with one idea, though it was a bit clich. In the films final scenecherished by millions of fans worldwidethe eccentric title character announces he is giving his entire factory to Charlie Bucket, a kind-hearted, honest, but poor boy who lives with his widowed mother and four bedridden grandparents in the slums of an unnamed European city. As Charlies disbelief turns to gratitude, Wonka hugs the boy, then tells him, But Charlie, dont forget what happened to the man who suddenly got everything he always wanted. He lived happily ever after, Wonka replies, smiling. Of course he did. It is a movie, after all. Hollywood is notorious for its happy endings, but such closure is not as readily found off-screen. Fairy tales and their all-is-well finales are pure fiction; the real world doesnt work that wayits cold, inconsistent, and oftentimes unfair. It offers no guarantees on contentment. Joy can be particularly elusive in business, even for companies that follow Wonkas guide to eternal euphoria. Apple Inc.s Cinderella-like evolution, for example, s Continue reading >>

    Medtronic Ventures Deeper Into China

    Medtronic Ventures Deeper Into China

    Brian Robisons release opens door for pair of talented, young Vikings he mentored Within five to 10 years, Medtronic officials expect China to leapfrog Japan and become the second-largest market behind the U.S. for the companys medical-technology products. The Fridley-based manufacturer took another step late Monday toward realizing that forecast with a planned $221 million purchase of a 15 percent equity stake in Shandong Weigao Group Medical Polymer Co. Ltd., a maker of orthopedic products. Pending regulatory approval, Medtronic will have a 51 percent interest in a separate joint venture with the Chinese company. The partnership will market Medtronics spinal products in China along with Weigaos therapies for trauma, as well as hip, shoulder and spine problems. We view Weigao as an ideal strategic partner, said Bill Hawkins, Medtronic chief executive officer, in a news release. Weigao has a broad orthopedic and trauma product line that compliments Medtronics offerings. China is key to our global strategy as we continue to expand our geographic footprint, Hawkins said. China is attractive because the market is huge and relatively untapped for many companies, said David Heupel, a portfolio manager with Thrivent Financial in Minneapolis. But questions remain, he said, about what sort of access to medical technology Chinese citizens will have and at what price. The question is whether anyone is going to make any money over there because whos going to pay for the technology? Heupel said. While the joint venture with Weigao is new, Medtronics business interest in China is not. Hawkins outlined his vision during an October investors conference in which he noted Medtronic already has 800 people working in China. Those workers are spread among eight operating units in 13 offic Continue reading >>

    Medtronic Ceo Eyes Acquisitions In China

    Medtronic Ceo Eyes Acquisitions In China

    In response to policy and market changes, Medtronic is adopting a new strategy in China, expanding its portfolio of value products instead of relying on premium device sales. The company also is eyeing potential acquisitions among local players in the Chinese device market. Medtronic CEO Omar Ishrak recently told the Wall Street Journal that, despite recent challenges, the sheer size of China's market makes it a compelling priority for device companies. Were completely bullish on China, Ishrak told the WSJ. Its a numbers game. This will be the largest market and its not a debate. Its a matter of when. China's medical device market is expected to be worth $18 billion by 2018, up 29 percent from 2014, according to London-based consulting firm L.E.K. That puts China ahead of Germany, and behind only the United States and Japan by the end of the decade. The Hong Kong Trade and Development Council (HKTDC) estimates that the local Chinese device market was worth $34.51 billion in 2014, and a McKinsey & Co. report from last year predicts the sector expanding 20 percent annually. Like Medtronic, other multinational device companies with an established presence in China are re-thinking their strategies in that market. For example, Johnson & Johnson recently reaffirmed its commitment to the Chinese market by inking large deals with local suppliers of its blood glucose and trauma products. As a whole, Medtronic is ramping up its annual sales growth in emerging markets to 15 percent, at constant currency rates, from the current 12 percent, Ishrak told the WSJ. The device maker also is moving into community hospitals outside Chinas big cities to sell surgical tools, cardiac devices, and spinal implants that cost less than its premium lines, the report said. The shift to value produ Continue reading >>

    Medtronic, Inc.: Private Company Information - Bloomberg

    Medtronic, Inc.: Private Company Information - Bloomberg

    Medtronic, Inc. manufactures and sells device-based medical therapies. Its products include pacemakers; insertable cardiac monitors; implantable defibrillators; leads and delivery systems; ablation products; electrophysiology catheters; coronary and peripheral stents and related delivery systems; therapies for uncontrolled hypertension; endovascular stent graft systems; heart valve replacement technologies; and cardiac tissue ablation systems. The company also offers products for spine; bone graft substitutes; biologic products; trauma and implantable neurostimulation therapies; and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, ov... Medtronic, Inc. manufactures and sells device-based medical therapies. Its products include pacemakers; insertable cardiac monitors; implantable defibrillators; leads and delivery systems; ablation products; electrophysiology catheters; coronary and peripheral stents and related delivery systems; therapies for uncontrolled hypertension; endovascular stent graft systems; heart valve replacement technologies; and cardiac tissue ablation systems. The company also offers products for spine; bone graft substitutes; biologic products; trauma and implantable neurostimulation therapies; and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis. Additionally, it manufactures and sells image-guided surgery and intra-operative imaging systems. The company provides insulin pumps; continuous glucose monitoring systems; insulin pump consumables; and web-based therapy management solutions. Medtronic, Inc. was founded in 2015 and is headquartered in Minneapolis, Min Continue reading >>

    Etfs Holding Mdt | Medtronic Plc | Etf Channel | Www.etfchannel.com | Copyright 2009 - 2018, All Rights Reserved

    Etfs Holding Mdt | Medtronic Plc | Etf Channel | Www.etfchannel.com | Copyright 2009 - 2018, All Rights Reserved

    (ranked lower than approx. 52% of all stocks covered) Health care ETFs provide handsome returns year to date. Companies In The News are COTY,MDT,SJM,TJX ETFs Holding MDT | Medtronic PLC | ETF Channel | www.ETFChannel.com | Copyright 2009 - 2018, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counselfrom, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under nocircumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be heldliable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy . Video widget and ETF videos powered by Market News Video . Quote data delayed at least 20 minutes; ETF data powered by Ticker Technologies , and Mergent . Contact ETF Channel ; Meet Our Editorial Staff . Continue reading >>

    More in diabetes